“…In recent years, the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas systems containing CRISPR/Cas9, Cas12, Cas13, and Cas14 have been widely applied to biomedical research and clinical diagnostics. − Among these systems, Cas13a (previously known as C2c2) or Cas12a, as an RNA-guided ribonuclease, can be programmed with CRISPR RNAs (crRNAs) to nonspecifically cleave (termed trans -cleavage) nearby RNAs or DNAs, respectively, in the presence of its target RNA or DNA. − On average, this trans -cleavage activity activated by a single target nucleic acid can cleave numerous nonspecific nucleic acid strands at physiological temperature, resulting in signal amplification. − More importantly, compared to the previously reported signal amplification strategies including HCR, catalytic hairpin assembly, and DNA nanomachine, the CRISPR/Cas system can greatly simplify the operation difficulty and significantly improve the analytical performance of the biosensing platform without the need for complex nucleic acid sequence design and excessive experimental manipulations. Given these advantages, several CRISPR/Cas12a-assisted PEC biosensors have been developed for the sensitive detection of miRNAs. − Moreover, to further achieve a desired detection sensitivity, the CRISPR/Cas12a system was commonly integrated with nucleic acid pre-amplification for miRNA detection, such as polymerase chain reaction, rolling circle amplification, loop-mediated isothermal amplification, recombinase polymerase amplification, and so forth. − However, the integration strategies of the pre-amplification step and CRISPR assay are carried out in steps and usually involve the transfer of amplified products. It not only increases the detection time and operational complexity but also easily causes aerosol contamination.…”